Each vial dry substance contains:
Cefepime (as HCl with L-arginine)………..500mg
CEPIME is indicated in for the treatment of the infections listed below when caused by susceptible bacteria:
- Lower respiratory tract infections, including pneumonia and bronchitis
- Urinary tract infections, both complicated, including pyelonephritis, and uncomplicated skin and skin structure infections
- Intra-abdominal infections, including peritonitis and biliary tract infections
- Gynecologic infections
Empiric Therapy for Febrile Neutropenic Patients
Cefepime as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk of severe infection (for example, patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, with severe or prolong neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support efficacy of Cefepime monotherapy in such patients.
CEPIME is also indicated for surgical prophylaxis in patients undergoing intra-abdominal surgery.
- Children aged more than 2 months and weighing ≤ 40kg: 50mg/kg every 12 hours for 10 days; in more severe infection, the 8 hours interval between should be done.
- Children aged more than 2 months and weighing ≤ 40kg: 50mg/kg every 8 hours during 7 to 10 days.
- Empiric Therapy for Febrile Neutropenic Patients. Cefepime as monotherapy is indicated for empiric treatment of febrile neutropenic patients. with severe or prolong neutropenia),
Culture & Susceptibility studies should be performing when appropriate to determine susceptibility of the causative organism(s) to Cefepime. Empiric therapy with CEPIME may be instituted before results of susceptibility studies are known; however, once these results become available the antibiotic treatment should be adjusted accordingly. Because of its broad spectrum of bactericidal activity against gram-positive and gram-negative bacteria, CEPIME can be used as mono therapy prior to identification of the causative organism(s). In patients who are at risk of mixed aerobic-anaerobic infection, particularly if bacteria not susceptible to Cefepime may be present (see pharmacological properties, Mechanism of Action, Microbiology), concurrent initial therapy with an anti-anaerobic agent is recommended before the causative organism(s) is (are) known, once these result become available, combination therapy with CEPIME and other anti-infective agents may or may not be necessary, depending on the susceptibility profile.
1 Vial dry substance + 1 x 5 ml W.F.I ampoule